a Type A, 150 kD botulinum toxin in a dose of 100 U to 300 U,

a positively charged carrier component having an amino acid sequence of SEQ ID NO: 4; and

a pharmaceutically acceptable diluent for injection;

wherein the positively charged carrier is non-covalently associated with the botulinum toxin component; and

wherein said dose of the composition provides a single treatment comprising a plurality of injections and having at least a 20 week duration of effect in reducing the symptoms of cervical dystonia in the individual.

[0017b] In one aspect, the present disclosure refers to use of a Type A, 150 kD botulinum toxin for the manufacture of an injectable composition for the treatment of cervical dystonia in an individual in need thereof, said composition comprising:

the botulinum toxin in a dose of 100 U to 300 U,

a positively charged carrier component having an amino acid sequence of SEQ ID NO: 4; and

a pharmaceutically acceptable diluent for injection;

wherein the positively charged carrier is non-covalently associated with the botulinum toxin component; and

wherein said dose of the composition provides a single treatment comprising a plurality of injections and having at least a 20 week duration of effect in reducing the symptoms of cervical dystonia in the individual.

[0017c] In one aspect, the present disclosure refers to a pharmaceutical composition in a sterile injectable formulation for use in treating cervical dystonia in an individual in need thereof who has been treated previously with the injectable composition, said composition comprising:

a Type A, 150 kD botulinum toxin in a dose of 100 U to 300 U,

a positively charged carrier component having an amino acid sequence of SEQ ID NO: 4; and

a pharmaceutically acceptable diluent for injection;

wherein the positively charged carrier is non-covalently associated with the botulinum toxin component; and

wherein said individual was previously treated with the dose and had a duration of effect of at least 20 weeks in reducing the symptoms of cervical dystonia in the individual and the treatment of said subject was at least 20 weeks after the previous treatment, wherein each treatment comprises a plurality of injections.

[0017d] In one aspect, the present disclosure refers to use of a Type A, 150 kD botulinum toxin for the manufacture of an injectable composition for a treatment of cervical dystonia in an individual in need thereof who has been treated previously with the injectable composition, said composition comprising:

the botulinum toxin in a dose of 100 U to 300 U,

a positively charged carrier component having an amino acid sequence of SEQ ID NO: 4; and

a pharmaceutically acceptable diluent for injection;

wherein the positively charged carrier is non-covalently associated with the botulinum toxin component; and

wherein said individual was previously treated with the dose and had a duration of effect of at least 20 weeks in reducing the symptoms of cervical dystonia in the individual and the treatment of said subject was at least 20 weeks after the previous treatment, wherein each treatment comprises a plurality of injections.

[0018] In another example, the disclosure provides effective doses and amounts of the compositions of this disclosure in the treatment of cervical dystonia that afford a long-lasting, sustained efficacy e.g., a response rate of long duration, following administration by injection to

Claims:

1. A pharmaceutical composition in a sterile injectable formulation for use in treating cervical dystonia in an individual in need thereof, said composition comprising:

a Type A, 150 kD botulinum toxin in a dose of 100 U to 300 U,

a positively charged carrier component having an amino acid sequence of SEQ ID NO: 4; and

a pharmaceutically acceptable diluent for injection;

wherein the positively charged carrier is non-covalently associated with the botulinum toxin component; and

wherein said dose of the composition provides a single treatment comprising a plurality of injections and having at least a 20 week duration of effect in reducing the symptoms of cervical dystonia in the individual.

2. Use of a Type A, 150 kD botulinum toxin for the manufacture of an injectable composition for the treatment of cervical dystonia in an individual in need thereof, said composition comprising:

the botulinum toxin in a dose of 100 U to 300 U,

a positively charged carrier component having an amino acid sequence of SEQ ID NO: 4; and

a pharmaceutically acceptable diluent for injection;

wherein the positively charged carrier is non-covalently associated with the botulinum toxin component; and

wherein said dose of the composition provides a single treatment comprising a plurality of injections and having at least a 20 week duration of effect in reducing the symptoms of cervical dystonia in the individual.

3. The use according to claim 2, wherein the composition does not locally diffuse from the site of injection following injection.

4. The use according to claim 2 or claim 3, wherein the duration of treatment effect comprises greater than 20 weeks.

5. The use according to claim 2 or claim 3, wherein the duration of treatment effect comprises greater than 24 weeks.

6. The use according to claim 2 or claim 3, wherein the duration of treatment effect comprises greater than 5 months.

7. The use according to claim 2 or claim 3, wherein the duration of treatment effect comprises greater than 6 months.

8. The use according to claim 2 or claim 3, wherein the duration of treatment effect comprises greater than 7 months.

9. The use according to claim 2 or claim 3, wherein the duration of treatment effect comprises greater than 8 months.

10. The use according to claim 2 or claim 3, wherein the duration of treatment effect comprises greater than 9 months.

11. The use according to claim 2 or claim 3, wherein the duration of treatment effect comprises at least 6 months through 10 months.

12. A pharmaceutical composition in a sterile injectable formulation for use in treating cervical dystonia in an individual in need thereof who has been treated previously with the injectable composition, said composition comprising:

a Type A, 150 kD botulinum toxin in a dose of 100 U to 300 U,

a positively charged carrier component having an amino acid sequence of SEQ ID NO: 4; and

a pharmaceutically acceptable diluent for injection;

wherein the positively charged carrier is non-covalently associated with the botulinum toxin component; and

wherein said individual was previously treated with the dose and had a duration of effect of at least 20 weeks in reducing the symptoms of cervical dystonia in the individual and the treatment of said subject was at least 20 weeks after the previous treatment, wherein each treatment comprises a plurality of injections.

13. Use of a Type A, 150 kD botulinum toxin for the manufacture of an injectable composition for a treatment of cervical dystonia in an individual in need thereof who has been treated previously with the injectable composition, said composition comprising:

the botulinum toxin in a dose of 100 U to 300 U,

a positively charged carrier component having an amino acid sequence of SEQ ID NO: 4; and

a pharmaceutically acceptable diluent for injection;

wherein the positively charged carrier is non-covalently associated with the botulinum toxin component; and

wherein said individual was previously treated with the dose and had a duration of effect of at least 20 weeks in reducing the symptoms of cervical dystonia in the individual and the treatment of said subject was at least 20 weeks after the previous treatment, wherein each treatment comprises a plurality of injections.